TIDMYGEN
Yourgene Health PLC
18 November 2021
Yourgene Health plc
("Yourgene" or the "Company")
DPYD screening recommended in Spain
Follows recommendations in Germany, Wales, England and
Belgium
Manchester, UK - 18 November 2021: Yourgene (AIM: YGEN), a
leading international molecular diagnostics group, welcomes the
publication in Clinical and Translational Oncology, titled: '
Consensus of experts from the Spanish Pharmacogenetics and
Pharmacogenomics Society and the Spanish Society of Medical
Oncology for the genotyping of DPYD in cancer patients who are
candidates for treatment with fuoropyrimidines(1) ', which
highlights the benefits of using a DPYD genotyping test to help
identify cancer patients with Dihydropyrimidine Dehydrogenase (
DPD) deficiency prior to treatment with the chemotherapeutic drug
5-Fluorouracil (5-FU).
5 -FU is a widely used chemotherapy agent in the treatment of
cancers, however for some patients who suffer from DPD deficiency
5-FU administered at normal therapeutic doses can cause severe and
sometimes lethal side effects. T his review is welcomed by Yourgene
as representatives of the Spanish Pharmacogenetics and
Pharmacogenomics Society ('SEFF') and the Spanish Society of
Medical Oncology ('SEOM'), provided the consensus opinion that: "in
the current era of personalized medicine, it is highly recommended
to genotype DPYD polymorphisms before administering
fuoropyrimidines."
Yourgene launched the Elucigene(R) DPYD assay, used to detect
the four most clinically relevant DPYD mutations, back in September
2019, and has already welcomed the screening recommendations in
Germany, Wales, NHS England and Belgium. An estimated two million
people globally are treated with fluoropyrimidines (including 5-FU)
each year(2) , with between 10-30% of these patients suffering
severe side effects associated with DPD deficiency(3) . The
screening enables clinicians to reduce the risk of increased
toxicity from 5-FU exposure in these patients by treatment with a
lower dose, or alternate drug therapy where indicated.
Lyn Rees, CEO of Yourgene, commented: "We are thrilled to see
DPYD screening recognised once again, this time in Spain by
representatives of SEFF and SEOM. We look forward to working
closely with our established distribution partner in the region,
Diagnostica Longwood, to support DPYD screening across labs in
Spain. By looking at how genes impact upon a patient's response to
drugs, personalised medicine is at the forefront of our healthcare
systems more than ever before, and we are pleased Yourgene is
supporting this progression within the oncology market."
References:
1 -
https://link.springer.com/article/10.1007%2Fs12094-021-02708-4
2 - D. Meulendijks et al./Cancer Treatment Reviews 50 (2016)
23-34
3 - Cancer Research UK https://bit.ly/2kLn1uT
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / 07584 391 303
/ Alice Woodings / 07407 804 654
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops integrated genomic technologies and services
enabling precision medicine. The group works in partnership with
global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics , Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFEALDLDLIL
(END) Dow Jones Newswires
November 18, 2021 02:00 ET (07:00 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Premaitha (LSE:NIPT)
Historical Stock Chart
From Nov 2023 to Nov 2024
